Abscopal response in a patient with fibrolamellar hepatocellular carcinoma following radiotherapy,The Lancet

当前位置： X-MOL 学术 › Lancet › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Abscopal response in a patient with fibrolamellar hepatocellular carcinoma following radiotherapy
The Lancet ( IF 98.4 ) Pub Date : 2024-12-19 , DOI: 10.1016/s0140-6736(24)02600-x
Jonathan D Schoenfeld, Daphne A Haas-Kogan, Allison F O'Neill

Section snippets

Contributors

DAH-K and AFO’N provided clinical care for this patient. JDS and AFO’N acquired the images. All authors wrote, reviewed, and revised the manuscript. Written consent for publication was obtained from the patient.

Declaration of interests

JDS declares support paid to his institution from Merck, BMS, Regeneron, Debiopharm, Seimens, and EMD Serono; consulting or participation on a scientific advisory board, travel fees, and payment for lectures from Castle Biosciences, Immunitas, IntraGel, LEK, ACI Clinical, SIRPant, Genentech, Merck KGaA, and EMD Serono; expert witness fees from Burns and White; stock options from Immunitas and IntraGel; and equity in Doximity; and patents pending: MAGEA1 immunogenic peptides, binding proteins

更新日期：2024-12-20

点击分享查看原文

点击收藏

阅读更多本刊新发论文